




New horizons and physics research opportunities in ion beam therapy

Katia Parodi, Ph.D.,
 Professor and Chair
 Department of Medical Physics,
 Ludwig-Maximilians-Universität München,
 Munich, Germany

The goal of radiation therapy



Dose, Radiation effect




The quest for an **external radiation** able to

Kill tumour cells
Spare healthy tissue



Basics of photon therapy

- Widely used photons (X-rays) transfer energy in few interactions with atomic electrons (mainly Compton scattering)
- Electrons can in turn damage DNA through
 - Direct ionization ($\approx 1/3$)
 - Creation of free radicals ($\approx 2/3$)
- Depth dose limited by exponential attenuation, after initial build-up
 - Different beam directions and intensity modulation




Photon therapy in the 21st century

Advanced photon therapy (IMRT, VMAT, IGRT, ART...)






Source: Elekta, Accuray, ViewRay

Basics of ion beam therapy




- Coulomb force interaction with tissue atoms
 - Energy loss with electrons ($\propto Z^2/v^2$)
 - Lateral deflection on nucleus (\downarrow for $\uparrow E, m$)
- Nuclear force interaction with nuclei
 - Attenuation of primary ions
 - Production of secondary particles and radiation



Newhauser and Zhang, Phys Med Biol 2015

Biological effectiveness




- Radiation effects are mainly due to complex DNA damage in cell nucleus
- Depend on ionization density of released electrons

Sparsely ionizing radiation

X-rays

Protons

(or high energy ^{12}C -ions
in entrance channel)




Simple DNA-damages (reparable)

Densely ionizing radiation

Low energy
 ^{12}C -ions

(in Bragg-Peak i.e. tumor)




Complex DNA-damages (limited reparable)




Enhanced relative biological effectiveness

Physical and biological advantages of ion beam therapy



Physical selectivity


- Depth-dose profile (Bragg-Peak)
- ↓ lateral scattering ($Z > 1$)



Biological effectiveness

- Elevated local ionization density
- ↑ Biological effectiveness
- ↓ Influence of tumour oxygenation


Carbon Ions in H_2O



Optimal differential effect $Z \approx 6$ (^{12}C ions)

Clinical rationale



- Inoperable tumours close to organs at risk
- Pediatric tumours
- Radioresistant tumours (^{12}C ions)



Karger and Jükel, DKFZ Heidelberg


Krämer et al, Adv Space Res 1994

Paving the way to ion beam therapy



1929: Cyclotron invention by E.O. Lawrence

1945: Synchrotron invention by E.M. McMillan and V.I. Veksler



1946: Proton therapy proposal by R.R. Wilson

Radiological Use of Fast Protons
ROBERT R WILSON
Radiol. 47 (1946) 487-91

- Protons can be used clinically
- Accelerators are available
- Maximum radiation dose can be deposited into the tumour sparing healthy tissues
- „Heavier nuclei, such as very energetic carbon atoms, may eventually become therapeutically practical“

Source: Wikipedia, Alamy stock photo, Lawrence Berkeley Lab/science photo library



Ion beam therapy: An historical perspective




Fundamental
Research

Clinical
Research

Clinical
Application

- 1946 *Ion therapy proposal for deep seated tumors*
- 1954 Lawrence Berkeley National Laboratory starts proton therapy in USA
- 1957 Uppsala starts proton treatment in Europe (Sweden)
- 1975 Lawrence Berkeley National Laboratory starts using heavy charged particles
- 1990 Opening of the Proton Therapy Center in Loma Linda
- 1993 Start of Carbon Ion Therapy in Chiba (Japan)
- 1997 Carbon ion therapy with 2D active delivery starts in Darmstadt (Germany)



Since 2000: Various clinical centers

Source: Lawrence Berkeley Lab/science photo library, Loma Linda University Medical Center





The worldwide spread of ion beam therapy




- > 90 proton therapy facilities (35 in USA)
- 13 carbon ion therapy facilities, 6 combined with protons (Germany, Italy, Austria, Japan, China)

Worldwide >200,000 patients treated with ions







Technological evolution of ion beam therapy




From fixed beamlines and passive beam delivery ...



... to rotating gantries and active beam delivery...





... to intensity modulated particle therapy (IMPT)



Sources: <http://www.schaer-engineering.ch/en/rptc.html14>, GSI Darmstadt, A. Lomax, PSI



Ion beam therapy in the 21th century



Is what we see what the patient receives?

Nuclear Physics for Medicine Report, NUPECC, 2014




Challenges in clinical practice




Increased sensitivity to uncertainties in beam delivery



- Anatomical changes (inter- and intra-fractions)
- Tissue stopping power (relative to water, SPR)



M. Engelsman et al, Seminars Rad. Onc. 2013



S. Schmid...K. Parodi, G. Dedes, PMB 2015




Bauer et al, HIT

How to reduce range uncertainties?




Mitigating range uncertainties in clinical practice





Usage of safety margins (non-isotropic)
 $\approx 2.5\text{-}3.5\% + 1\text{-}3\text{ mm}$

and conservative choice of beam angles



Paganetti, PMB 2012




In-vivo verification and adaptation?

Polf and Parodi, Phys Today 2015



In-room imaging for ion beam therapy



Anatomical imaging (as in modern photon therapy)

- Horizontal/vertical CT
- On-board Cone Beam CT (CBCT)
- *Magnetic Resonance Imaging ?*



Source: TPC, Northwestern Medicine, Oncoray Dresden, MGH Boston, IBA, MedPhoton; Hoffmann ...Parodi, RadOnc 2020




In-room imaging for ion beam therapy




Imaging of tissue stopping power properties (SPR, specific to ion beam therapy)


- *Dual Energy X-ray CT (DECT)*
- Commercially available
Enables patient-specific calibration
Improved SPR accuracy



- *Ion transmission imaging?*
- Under development
Enables direct SPR estimation
Low-dose imaging



Wolfahrt et al, IJROBP 2017







Oancea&Schulte, IEEE MIC 2018

LMU LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN **In-room imaging for ion beam therapy**

Imaging of tissue stopping power properties (SPR, specific to ion beam therapy)

Competitive performance of proton CT prototype vs dual-source DECT at much lower imaging dose

Ongoing efforts to translate this technology into clinical use



noise in beam	Low	High	Low
dose outside beam	High	Low	Low

Dedes, ..., Parodi, PMB 2019 ; Dedes...Parodi, Landry MP 2018

LMU LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN **Make the invisible visible**

Imaging particle beams for cancer treatment
 Jeremy C. Poff and Katja Parodi

Proton and carbon-ion radiotherapy are powerful tools for killing tumor cells but only if the particles deposit their energy where they're supposed to.

In 2018 approximately 1 in 7 deaths worldwide were due to cancer and a considerable 15 million cancer patients require radiotherapy either as the main or as an adjunct to their cancer treatment. Radiotherapy works as a cancer treatment by depositing energy through atomic and nuclear interactions in patient tissues and thereby damaging tumor cells. That energy deposition, known as the absorbed dose, is measured in units of joules per kilogram of tissue, or gray. The goal is to deliver the prescribed radiation treatment dose to the entire tumor volume while minimizing or sparing healthy tissue as much as possible.

Over the next few years, the proton and carbon-ion beams will be used to deliver the full treatment dose to the tumor volume. See the article by author Jeremy C. Poff and Katja Parodi in the journal *Physics Today*.

Proton and carbon-ion radiotherapy are powerful tools for killing tumor cells but only if the particles deposit their energy where they're supposed to.

Proton and carbon-ion beams have significantly increased since the year 2010. The distinct clinical advantage that ion beams provide over other cancer treatment modalities was first highlighted by Robert Wilson's "Bragg peak" in 1904, at which protons and carbon-ion beams deposit their energy in a nucleus in a highly localized manner. The Bragg peak is a result of the particles' loss of energy to ionize the target, gradually increasing with depth as the particles lose energy and subatomic particles are ejected. However, as the Bragg peak just before the tumor target. The depth of the Bragg peak is a function of the particle's initial energy and mass. By controlling the particle's initial energy, the beam's energy deposition can be precisely controlled to the tumor while sparing healthy tissue. The tumor can then be treated and the surrounding healthy tissue spared, in principle. But protons are less likely to penetrate past normal, long-distance and side effects are more likely to occur at their target.


Despite the promise and potential of the Bragg peak, the precision of radiotherapy is limited by the uncertainty in the particle's initial energy and mass. The 2015 distinct clinical advantage that ion beams provide over other cancer treatment modalities was first highlighted by Robert Wilson's "Bragg peak" in 1904, at which protons and carbon-ion beams deposit their energy in a nucleus in a highly localized manner. The Bragg peak is a result of the particles' loss of energy to ionize the target, gradually increasing with depth as the particles lose energy and subatomic particles are ejected. However, as the Bragg peak just before the tumor target. The depth of the Bragg peak is a function of the particle's initial energy and mass. By controlling the particle's initial energy, the beam's energy deposition can be precisely controlled to the tumor while sparing healthy tissue. The tumor can then be treated and the surrounding healthy tissue spared, in principle. But protons are less likely to penetrate past normal, long-distance and side effects are more likely to occur at their target.

Despite the promise and potential of the Bragg peak, the precision of radiotherapy is limited by the uncertainty in the particle's initial energy and mass. The 2015 distinct clinical advantage that ion beams provide over other cancer treatment modalities was first highlighted by Robert Wilson's "Bragg peak" in 1904, at which protons and carbon-ion beams deposit their energy in a nucleus in a highly localized manner. The Bragg peak is a result of the particles' loss of energy to ionize the target, gradually increasing with depth as the particles lose energy and subatomic particles are ejected. However, as the Bragg peak just before the tumor target. The depth of the Bragg peak is a function of the particle's initial energy and mass. By controlling the particle's initial energy, the beam's energy deposition can be precisely controlled to the tumor while sparing healthy tissue. The tumor can then be treated and the surrounding healthy tissue spared, in principle. But protons are less likely to penetrate past normal, long-distance and side effects are more likely to occur at their target.



Despite the promise and potential of the Bragg peak, the precision of radiotherapy is limited by the uncertainty in the particle's initial energy and mass. The 2015 distinct clinical advantage that ion beams provide over other cancer treatment modalities was first highlighted by Robert Wilson's "Bragg peak" in 1904, at which protons and carbon-ion beams deposit their energy in a nucleus in a highly localized manner. The Bragg peak is a result of the particles' loss of energy to ionize the target, gradually increasing with depth as the particles lose energy and subatomic particles are ejected. However, as the Bragg peak just before the tumor target. The depth of the Bragg peak is a function of the particle's initial energy and mass. By controlling the particle's initial energy, the beam's energy deposition can be precisely controlled to the tumor while sparing healthy tissue. The tumor can then be treated and the surrounding healthy tissue spared, in principle. But protons are less likely to penetrate past normal, long-distance and side effects are more likely to occur at their target.

Despite the promise and potential of the Bragg peak, the precision of radiotherapy is limited by the uncertainty in the particle's initial energy and mass. The 2015 distinct clinical advantage that ion beams provide over other cancer treatment modalities was first highlighted by Robert Wilson's "Bragg peak" in 1904, at which protons and carbon-ion beams deposit their energy in a nucleus in a highly localized manner. The Bragg peak is a result of the particles' loss of energy to ionize the target, gradually increasing with depth as the particles lose energy and subatomic particles are ejected. However, as the Bragg peak just before the tumor target. The depth of the Bragg peak is a function of the particle's initial energy and mass. By controlling the particle's initial energy, the beam's energy deposition can be precisely controlled to the tumor while sparing healthy tissue. The tumor can then be treated and the surrounding healthy tissue spared, in principle. But protons are less likely to penetrate past normal, long-distance and side effects are more likely to occur at their target.


Different emission mechanisms



PET or PG imaging?




PG (ideal 100% detection efficiency, volumetric imaging, no background) vs post-treatment PET for proton therapy



Ideal PG signal shows better correlation to range due to lower energy threshold of reaction cross sections



Moteabb, España, Paganetti, PMB 2011

PET or PG imaging?



PET

- Proven imaging technologies, with many ongoing developments for nuclear medicine applications (eg ultra-fast TOF)
- Intrinsically 3D, possibility of combination with tracer imaging
- Issues of washout and „slow“ response




PG

- Requires dedicated instrumentation for detection of multi-MeV photons
- Not all implementations provide 3D imaging
- Online, real-time (no washout issue)
- Possibility to provide spectroscopic information


Ferraro et al, Sci Rep 2018

Richter et al, Radiother Oncol 2016





LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN


Further new trends combining PET&PG?




QST International Research Initiative (IRI)
Whole gamma imaging (WGI) research






Taiga Yamaya Katia Parodi





Scatterer
Absorber





Tashima et al, PMB 2020


Marco Durante Katia Parodi




Hybrid γ -PET detector for future use with RIB beams at FAIR/GSI




Beamtime in Feb 2021 @ GSI




Safari ... Yamaya, Thirolf, Parodi, to be presented at PTCOG 2021
Nitta, Binder, ...Kang, Yamaya, Thirolf, Parodi, IEEE 2019, to be published




Compton imager






LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN

Integration in clinical workflow




Comparison meas. vs. prediction so far based on engines (mostly MC) external to treatment planning system (TPS)
Analytical PET & PG calculation in a research version of TPS "RayStation" for p , currently under extension for ^{12}C




(data courtesy J. Bauer, J. Debus)

TPS dose




MC dose




Dose (Gy)

TPS PG




MC PG




Number PE ($\times 10^6$)

On Simulated data




On measured data



Dose (Gy $\text{mm}^2 / ^{12}\text{C}$)

Depth [mm]

Opening the prospects of dose quantification



Hofmann, Pinto... Yamaya, Parodi, PMB 2019

Pinto, ...Parodi. PMB 2020





New horizons in small animal research

Bridging the gap: small animal radiotherapy research


Emerging irradiation platforms for protons and heavier ions

NEWSFEED

Apr 13, 2015

University of Washington buys SARRP system for pre-clinical proton therapy

6 April 2015 - University of Washington (UW) has purchased an Xstrahl Life Sciences SARRP platform and is integrating it with their Pre-Clinical Proton Therapy Facility.



PARTICLE THERAPY / RESEARCH UPDATE

Small-animal irradiation platform performs preclinical proton studies

23 Jul 2019 Tara Freeman

physicsworld



The Penn research team with the SARRP on rails. (Courtesy: Eric Dillendorfer)

Physics in Medicine & Biology

IPEM Institute of Physics and Engineering Medicine

PAPER

Design and commissioning of an image-guided small animal radiation platform and quality assurance protocol for integrated proton and x-ray radiobiology research

Michelle M Kim, Preston Irwin, Khayrullo Shoniburov, Benjamin J Verginadis, Keith A Congel, Constantinos Koussios, James M Metz, Lei Dong and Eric S Dillendorfer

10.1088/1741-2552/ab0000

Xstrahl

Home Medical Life Sciences About Us News Xstrahl US

Home Pre-Clinical Systems By Innovation Xstrahl in Action Events Publications User Spotlight

XSTRAHL LAUNCHES THE NEW SARRP BEAMLINE FOR PROTON, PHOTON, CARBON AND FLASH PRE-CLINICAL EXPERIMENTS

August 28th, 2019


However mostly limited to morphological image guidance and passive beam shaping



The SIRMIO project

Small animal proton irradiator for research in molecular image-guided radiation-oncology

- Realize and demonstrate **prototype system** for
- precision, image-guided small animal proton irradiation
 - integration in experimental beamlines of clinical facilities



- WP1: High beam quality
- WP-2a...c: Innovative image guidance beyond morphology
- WP-3: Adaptive planning and delivery

Parodi et al, Acta Oncol 2019

WP1: Beamline


Energy degradation, transport and refocusing of lowest-energy (70 – 100 MeV) clinical beam

Requirements:


- Transport of energies between 20 and 50 MeV
- Sub-millimeter (sigma) spot sizes at isocenter
- Beam currents appropriate for treatment

Approach:


- Model lowest-energy clinical beam from exp. data (RPTC)
- Optimization of collimators & PMQ after variable degrader
- Monte Carlo (MC) validation of particle optics calculations
- MC testing of expected outcome for different facilities



Schematic drawing of the SIRMIO beamline



MC model of the beam transport (p in blue)



Magnets being characterized prior to first exp. tests

Gerlach, Pinto,
Kurichiyani...Parodi,
PMB 2020

RPTC: Munich; CAL: Nice; PSI: Villigen; APSS: Trento; DCPT: Aarhus

WP2a: Proton radiography/tomography



Pre-treatment radiographic & tomographic imaging

- Proton transmission imaging for recovery of tissue relative stopping power (to water, SPR)
- Vertical irradiation position for imaging & treatment
- In-house holder accommodating sterility, anaesthetization and temperature stabilization, with minimal material budget and possibility of acoustic coupling

Two solutions being developed for *conventional* & *synchrocyclotron-based* facilities

1. Single particle tracking

- Low dose (< 1 mGy per radiography)
- Accounts for Coulomb scattering
- **Complex detectors**






Detailed Monte Carlo modeling including all components and realistic beam

WP2a: Proton radiography/tomography

Optimization of tracker and range telescope design for best image quality

Image reconstruction using a TVS OS-SART algorithm



Currently finalizing detector production & assembly for first beam testing


Bortfeldt et al, MPGD 2019; Meyer PhD thesis LMU; Meyer et al PMB 2020

WP2a: Proton radiography/tomography

Two solutions being developed for conventional & synchrotron-based facilities

2. Commercial pixel-detectors

- High dose (> 1 mGy per radiography)
- Do not account for Coulomb scattering
- Relatively **simple detectors**
- **Integrating / single** particle detection




Comparing performance of

- Commercially available large area **CMOS detector** (49.5 × 49.5 μm² pixel size) with linear signal decomposition method to determine WET
- **Minipix/Timepix**, potentially able of single particle detection (in collaboration with Advacam Radiation imaging Solutions)



Preliminary Exp. results




Schnürle PhD project, Würfl et al, IEEE MIC 2020

LMU LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN


In-vivo range monitoring

Two solutions being developed for **conventional** & **synchrotron-based** facilities

WP2.c Development of dedicated in-beam PET scanner to detect irradiation induced activity



WP2.b Exploitation of thermoacoustic emissions from pulsed beam delivery (ionoacoustics)




Nitta et al, IEEE MIC 2019, Lovatti PhD project


Kellnberger, ... Parodi, Ntziachristos, Sci Rep 2016

LMU LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN


WP2b: Ionoacoustics/Ultrasound



Comparison of technologies



Comparison to ideal simulation





Ongoing development of alternative sensor technologies (e.g., PVDF)


- Larger bandwidth and better sensitivity of CMUT* vs PZT:**
- Increased SNR
 - Independent of beam energy and probe position
 - Bi-modality imaging (US / Ionoacoustics)

Image reconstruction and co-registration

- Evaluation of optimal sensor position for multilateration or image reconstruction
- Development of 3D printed multimodal mouse phantom
- Ionoacoustics/US co-registration with single sensor in heterogenous media



Preliminary Exp. results



Lascaud ... Parodi, talk at Small Animal Precision IGRT conference; Lascaud ... Parodi, MIC 2020; Dash MSc thesis

Requirements of high-sensitivity, (sub)-millimeter spatial resolution, in-beam integration

Proposed novel spherical design

- 56 LYSO DOI detectors and spherical design (7-12% efficiency)
- Spatial resolution ≤ 1.0 mm FWHM
- Wide opening for beam, mouse holder & ultrasound transducers

First in-beam operation


- 8 LYSO DOI successfully tested in $^{10,11}\text{C}$ beams @ GSI



Ongoing work & Next steps


- Characterization and assembly of all 56 LYSO DOI detectors
- Finalization of simulation and image reconstruction framework
- Final evaluation of scanner imaging performance and first in-beam tests in proton beams

3-layer DOI block with 0.9 pixel width




Nitta, Lovatti...Yamaya, Thirolf, Parodi, IEEE NSS-MIC 2019, 2021; Lovatti PhD project; Haghani MSc thesis

WP3: Adaptive treatment workflows



Beamline optimization and future SIRMIO operation requires TPS planning system

- License agreement and research collaboration agreement with RaySearch Laboratories




Ongoing work & Next steps

- Validation of μ -RayStation against full Monte Carlo transport code
- Systematic planning studies for final optimization of setup and assessment of pCT image quality
- Import/handling of all SIRMIO imaging data to develop adaptive treatment workflow
- μ -RayStation upgrade to explicitly handle SIRMIO beamline (with RaySearch)

Average range error (0.87 ± 0.98)%

Meyer et al, PMB 2020; Pinto (LMU), Nilsson, Traneus (RaySearch), PhD thesis S. Meyer, MSc thesis S. Kundel & L. Zott


SIRMIO status & outlook



Several WPs ongoing to realize prototype SIRMIO platform

Several beamtimes scheduled in summer/fall 2021 to test performance of different components, prior to final demonstration early 2022






Final system will be adaptable to different proton centers and could thus offer a versatile platform for precision small animal radiation research



Parodi ... Würfl, Acta Oncologica 2019; Meyer...Parodi PMB 2020



New frontiers to widen therapeutic window?





Increased tumour cell killing


Reduced damage of normal tissue



Laser-driven ion acceleration



From RF-accelerators (~ kV/mm) to optical systems (~ MV/μm)?



Sources: West German Proton Therapy Center & HIT Heidelberg




LION @ Center for Advanced Laser Application




Laser-driven proton source with new targets and beamline (AG Prof. Schreiber)


γ -PET



Can provide instantaneous ultra-high dose rate ($\sim 1\text{Gy/ns}$) for FLASH investigations




Proton radiography



New detector prototypes (collaboration with Wollongong University, Australia)

Ionoacoustics



LEX Photonics

CALA



L. Tran (2015), IEEE Trans Nuc Sci, 62, 6

PhD thesis S. Lehrack, S. Aldawood, S. Liprandi, M. Würli; project F. Englbrecht (ongoing)



Conclusion & Outlook

- Promising techniques for full exploitation of ion therapy advantages in clinical practice close to or just starting clinical translation & evaluation
- Reduction of uncertainties at planning & delivery stage will enable more accurate dose delivery and likely impact clinical outcome
- New technologies for precision pre-clinical research will support ongoing studies on new frontiers effects to widen therapeutic window






LUDWIG-
MAXIMILIANS-
UNIVERSITÄT
MÜNCHEN

Research at the LMU Department of Experimental Medical Physics

Laser Ion Acceleration



Range verification in PT







Image guidance



Dosimetry



Detector development



LUDWIG-
MAXIMILIANS-
UNIVERSITÄT
MÜNCHEN

Acknowledgement

LMU Department of Experimental –Medical Physics



www.med.physik.uni-muenchen.de

Collaborations

- C. Belka, K. Lauber, G. Landry et al, LMU Klinikum
- R. Schulte et al, Loma Linda University
- T. Yamaya, NIRS
- E. Traneus, R. Nilsson RaySearch
- M. Vidal, J. Herault, CAL
- A. Savoia, University Roma Tre
- F. Verhaegen, MAASTRO
- P. Poulsen, M. Sitarz, C. Grau, Aarhus
- A. Mairani et al, HIT & CNAO
- A. Ferrari et al, CERN
- ...

Funding



European
Research
Council



Alexander von Humboldt
Stiftung/Foundation



Thank you for your attention